BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24311781)

  • 1. Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.
    Cattaneo M; Baronchelli S; Schiffer D; Mellai M; Caldera V; Saccani GJ; Dalpra L; Daga A; Orlandi R; DeBlasio P; Biunno I
    J Biol Chem; 2014 Jan; 289(5):2826-38. PubMed ID: 24311781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of endoplasmic reticulum (ER) stress in gliomas.
    Markouli M; Strepkos D; Papavassiliou AG; Piperi C
    Pharmacol Res; 2020 Jul; 157():104823. PubMed ID: 32305494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
    Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
    Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.
    Yoo YD; Lee DH; Cha-Molstad H; Kim H; Mun SR; Ji C; Park SH; Sung KS; Choi SA; Hwang J; Park DM; Kim SK; Park KJ; Kang SH; Oh SC; Ciechanover A; Lee YJ; Kim BY; Kwon YT
    EMBO Rep; 2017 Jan; 18(1):150-168. PubMed ID: 27993939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability.
    Sheikh S; Saxena D; Tian X; Amirshaghaghi A; Tsourkas A; Brem S; Dorsey JF
    Mol Cancer Res; 2019 May; 17(5):1102-1114. PubMed ID: 30642878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.
    Sareddy GR; Viswanadhapalli S; Surapaneni P; Suzuki T; Brenner A; Vadlamudi RK
    Oncogene; 2017 Apr; 36(17):2423-2434. PubMed ID: 27893719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
    Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
    Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
    Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
    Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic Acid Sensitizes Glioma Cells to Luteolin Through Induction of Apoptosis and Autophagy via Akt Signaling.
    Han W; Yu F; Wang R; Guan W; Zhi F
    Cell Mol Neurobiol; 2021 Nov; 41(8):1625-1634. PubMed ID: 32719967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.
    Peng L; Ming Y; Zhang L; Zhou J; Xiang W; Zeng S; He H; Chen L
    FASEB J; 2020 Apr; 34(4):5128-5143. PubMed ID: 32067282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
    Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
    J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
    Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
    J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
    Epple LM; Dodd RD; Merz AL; Dechkovskaia AM; Herring M; Winston BA; Lencioni AM; Russell RL; Madsen H; Nega M; Dusto NL; White J; Bigner DD; Nicchitta CV; Serkova NJ; Graner MW
    PLoS One; 2013; 8(8):e73267. PubMed ID: 24039668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
    Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
    Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NFAT1-Mediated Regulation of NDEL1 Promotes Growth and Invasion of Glioma Stem-like Cells.
    Jiang Y; Song Y; Wang R; Hu T; Zhang D; Wang Z; Tie X; Wang M; Han S
    Cancer Res; 2019 May; 79(10):2593-2603. PubMed ID: 30940662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
    Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
    Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma.
    Luwor R; Morokoff AP; Amiridis S; D'Abaco G; Paradiso L; Stylli SS; Nguyen HPT; Tarleton M; Young KA; O'Brien TJ; Robinson PJ; Chircop M; McCluskey A; Jones NC
    Cancer Invest; 2019; 37(3):144-155. PubMed ID: 30907150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.